**TITLE:**

**Isolation of Extracellular Vesicles from Murine Bronchoalveolar Lavage Fluid Using an Ultrafiltration Centrifugation Technique**

**AUTHORS & AFFILIATIONS:**

Tanyalak Parimon1, Noman E. Garrett III1, Peter Chen1,2, Travis Antes3

1Department of Medicine, Division of Pulmonary and Critical Care, Women’s Guild Lung Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America

2Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America

3Department of Medicine, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States of America

**Corresponding Author:**

Tanyalak Parimon (Tanyalak.Parimon@cshs.org

Tel.: 424.315.2866

**E-mail Addresses of the Co-authors:**

Norman E. Garrett III (Norman.GarrettIII@cshs.org)

Peter Chen (Peter.Chen@cshs.org)

Travis Antes (Travis.Antes@cshs.org)

**KEYWORDS:**

Extracellular vesicles, exosomes, ultrafiltration centrifugation, ultracentrifugation, isolation technique, bronchoalveolar lavage fluid

**SUMMARY:**

Here, we describe two extracellular vesicle isolation protocols, ultrafiltration centrifugation and ultracentrifugation with density gradient centrifugation, to isolate extracellular vesicles from murine bronchoalveolar lavage fluid samples. The extracellular vesicles derived from murine bronchoalveolar lavage fluid by both methods are quantified and characterized.

**ABSTRACT:**

Extracellular vesicles (EVs) are newly discovered subcellular components that play important roles in many biological signaling functions during physiological and pathological states. The isolation of EVs continues to be a major challenge in this field, due to limitations intrinsic to each technique. The differential ultracentrifugation with density gradient centrifugation method is a commonly used approach and is considered to be the gold standard procedure for EV isolation. However, this procedure is time-consuming, labor-intensive, and generally results in low scalability, which may not be suitable for small-volume samples such as bronchoalveolar lavage fluid. We demonstrate that an ultrafiltration centrifugation isolation method is simple and time- and labor-efficient yet provides a high recovery yield and purity. We propose that this isolation method could be an alternative approach that is suitable for EV isolation, particularly for small-volume biological specimens.

**INTRODUCTION:**

Exosomes are the smallest subset of (EVs), 50 - 200 nm in diameter, and have multiple biological functions across a diverse array of signaling processes1-5. They govern cellular and tissue homeostasis primarily by facilitating intercellular communication through cargo molecules such as lipids, proteins, and nucleic acids6-9. One critical step in EV research is the isolation process. Differential ultracentrifugation (UC), with or without density gradient centrifugation (DGC), is considered the gold standard approach, but this method carries major limitations, including inefficient EV recovery rates and low scalability10-12, that restrict its best utilization to larger volume samples, such as cell culture supernatant or high exosome production specimens. The advantages and disadvantages of other methods, such as size exclusion by ultrafiltration or chromatography, immunoaffinity isolation by beads or columns, and microfluidics, are well described, and modern supplemental procedures have been developed to overcome and minimize technical limitations in each approach11-15. Others have shown that an ultrafiltration centrifugation (UFC) with a nanoporous membrane in the filter unit is an alternative technique that provides comparable purity to a UC method16-18. This technique could be considered as one of the alternative isolation methods.

Bronchoalveolar lavage fluid (BALF) contains EVs that possess numerous biological functions in various respiratory conditions19-22. Studying BALF-derived EVs entails some challenges due to the invasiveness of the bronchoscopy procedure in humans, as well as a limited amount of lavage fluid recovery. In small laboratory animals such as mice, only a few milliliters can be recovered in normal lung conditions, even less in inflamed or fibrotic lungs23. Consequently, collecting a sufficient amount of BALF for EV isolation by a differential ultracentrifugation for downstream applications may not be feasible. However, isolating correct EV populations is a crucial factor for studying EV biological functions. The delicate balance between efficiency and efficacy continues to be a challenge in well-established EV isolation methods.

In this current study, we demonstrate that a centrifugal ultrafiltration approach, utilizing a 100-kDa molecular weight cut-off (MWCO) nanomembrane filter unit, is suitable for small-volume biological specimen such as BALF. This technique is simple, efficient, and provides high purity and scalability to support the study of BALF-derived EVs.

**PROTOCOL:**

The utilization of animals and all animal procedures were approved by the Institutional Animal Care and Use Committees (IACUC) at Cedars-Sinai Medical Center (CSMC).

1. **Murine Bronchoalveolar Lavage Fluid (BALF) Collection and Preparation**
   1. **BALF collection**
      1. Euthanize mice with a cocktail of ketamine (300 mg/kg) and xylazine (30 mg/kg) *via* the intraperitoneal route followed by cervical dislocation.
      2. Insert a 22-G angiocatheter into the trachea. Attach an insulin syringe containing 1 mL (mL) of ice-cold sterile Dulbecco’s phosphate buffer saline (DPBS) and instill 1 mL of DBPS into both lungs through the angiocatheter.
      3. Slowly withdraw the syringe plunger to retrieve BALF and dispense the BALF into a 50-mL conical tube. Keep the BALF on ice.
      4. Repeat steps 1.1.2 and 1.1.3 3x (4x in total in each mouse).

Note: Approximately 0.8 mL is generally retrieved per milliliter of instillation. Also, the following steps can be performed for individual mice (*i.e.*, 3 mL of BALF), but pooling multiple BALF samples will allow the isolation of a larger batch of EVs for consistency in downstream experiments.

* 1. **BALF preparation**
     1. Pool BALF from 25 mice and divide it into two equal sets (~35 mL per aliquot).
     2. Centrifuge the BALF at 400 x g, at 4 °C for 5 min, to remove cells and other cellular debris and collect the supernatant.
     3. Centrifuge the supernatant at 1,500 x g, at 4 °C for 10 min, to remove cell debris. Collect the supernatant and proceed to the EV isolation steps.

1. **Isolation of Extracellular Vesicles from Murine Bronchoalveolar Lavage Fluid**

Note: In this study, two EV isolation techniques, namely UFC and ultracentrifugation with buoyant density gradient centrifugation (UC-DGC), are used to isolate EVs from BALF. The detailed protocol of each method is described below.

* 1. **Ultrafiltration centrifugation (UFC) enrichment method**

Note: This method was modified from a previously described protocol10.

* + 1. Filter the supernatant from step 1.2.3 through a 0.2-μm sterile syringe filter and keep the filtered BALF on ice.

Note: This is a size exclusion step whereby only vesicles smaller than 200 nm are collected.

* + 1. Equilibrate the 100-kDa MWCO centrifugal filter unit with sterile DPBS for 10 min. Centrifuge the centrifugal unit at 1,500 x g for 10 min at 4 °C to discard the DPBS.

CAUTION: Once the membrane in the filter device is equilibrated with DPBS, the membrane must be kept wet at all time until the device is used.

* + 1. Fill the filter unit with 15 mL of BALF sample from step 2.1.1 and centrifuge at 3,000 x g for 30 min at 4 °C. The flow-through BALF can be discarded or collected into a separate canonical tube and stored at (-)80 °C for future use.
    2. Repeat step 2.1.3 for the remaining 0.2-µm-filtered BALF.

Note: It took three repetitions of centrifugations to sufficiently concentrate the BALF EVs from the original starting volume of 35 mL. This resulted in 1 - 1.5 mL of retentate.

* + 1. Wash the retentate with 14 mL of sterile DPBS by a gently pipetting repetitively. Centrifuge the filter unit at 3,000 x g, at 4 °C for 30 min, to remove the DPBS and to concentrate the EV retentate.
    2. Collect the concentrated BALF-derived EVs from the filter device by inserting a pipettor into the bottom of the filter device and withdrawing the sample using a side-to-side sweeping motion to ensure total recovery.
    3. Aliquot the BALF-derived EVs and store them at (-)80 °C for further particle quantification and characterization (see step 3).
  1. **Ultracentrifugation (UC) with buoyant density gradient centrifugation (DGC)**

Note: The following protocol was modified from the previously described protocol24.

* + 1. Transfer the supernatant from step 2.1.1 into a 37-mL ultracentrifuge tube and centrifuge the sample at 10,000 x g for 30 min at 4 °C using ultracentrifuge. Collect the supernatant and centrifuge at 100,000 x g, at 4 °C for 60 min. While the EV pellets are centrifuged, prepare different concentrations of buoyant density gradient buffers (**Table 1**) for step 2.2.3.
    2. Discard the supernatant and resuspend the EV pellets in 200 μL of DPBS.
    3. Mix the EV suspension with 300 μL of 50% iodixanol working solution (**Table 1**) and transfer it to the 15-mL ultracentrifuge tube. On top of the 50% iodixanol-EV mixture suspension, sequentially layer the following buffer solution in the order from the bottom to the top: 30% iodixanol (4.5 mL), 25% of iodixanol (3 mL), 15% iodixanol (2.5 mL), and 5% iodixanol (6 mL). Centrifuge at 100,000 x g, at 4 °C for 230 min.

Note: The buoyant density gradient is based on the percent of iodixanol scaling with the highest concentration (50%) at the bottom to the lowest concentration (5%) at the top. To generate different concentrations of iodixanol, various amounts of homogenization medium (**Table 1**) were mixed with working solution (50% iodixanol).

* + 1. Collect the 15% and 25% fraction and dilute them in sterile DPBS to bring up the volume to 15 mL. Transfer them to a new small ultracentrifuge tube and centrifuge at 100,000 x g,at 4 °C for 60 min.
    2. Discard the supernatant and resuspend the EV pellets in 50 μL of sterile DPBS for further characterization.

1. **Extracellular Vesicle Quantification**

Note: The BALF-derived EVs recovery yield is quantitated with two metrics.

* 1. **Nanoparticle tracking analysis (NTA) measurement**
     1. Dilute the EV sample at 1:200 - 1:500 in 1 mL of DPBS and load the sample into an insulin syringe. Attach a sample syringe to a syringe pump and begin to measure the particle numbers and size (see **Table of Materials**).
     2. Set the camera level at 14 and the detection threshold at 1 for all sample measurements. Five repetitive measurements with 1,500 frames in 30 s were recorded for each sample, with a delay of 20 s between reads. Combine and average the data for final concentration and size reports.

Note:For accurate capturing of all particles, adjust the camera level as appropriate to visualize all particles and use similar settings for all sample measurements in each experiment.

* 1. **Protein quantification**

Note: The bicinchoninic acid (BCA) protein assay was used to measure the protein concentration of the BALF-derived EVs.

* + 1. Solubilize the EV samples in 1x lysis buffer.
    2. Quantify the amount of protein in the BALF-derived EVs per BCA standard protocol using colorimetric detection by measuring the absorbance at 560 nm in a plate reader.

1. **Detection of BALF-derived Extracellular Vesicles**

Note: Commonly known exosome surface marker proteins (TSG101, CD63, CD81, and CD9) were used to verify EV recoveries by SDS-PAGE and immunoblotting and flow cytometry analysis.

* 1. **SDS-PAGE and immunoblotting**
     1. Dissolve an equal amount of EV proteins of each sample with a blotting loading buffer (lithium dodecyl sulfate) and 50 mM dithiothreitol (DTT) in a 1.6-mL tube. Heat the samples at 70 °C for 10 min.
     2. Load the samples from step 4.1.1 into a 4% - 12% Bis-Tris Plus acrylamide gel and run electrophoresis (150 volts, 35 mA) for 35 min.
     3. Transfer proteins to a nitrocellulose membrane using a dry transfer method.
     4. Block the membrane with 5% skimmed milk for 60 min, rocking at room temperature (RT).

* + 1. Incubate the membrane with an antibody to an EV surface protein marker, Tumor Susceptibility Gene 101 (TSG101), at 1:500 dilution in 5% BSA in Tris-buffered saline Tween-20 (TBST) at 4 °C, rocking overnight.
    2. The next day, wash the membrane 3x, 10 min each wash, in TBST buffer, and incubate it with anti-rabbit IgG, an HRP-linked antibody, at 1:5,000 dilution for 60 min at RT.
    3. Wash the membrane 3x, 10 min each wash, in TBST buffer. Develop the membrane with chemiluminescent HRP antibody detection reagent and image (see **Table of Materials** for imaging system).
  1. **Flow cytometry**
     1. Dilute BALF-derived EVs in 49 μL of PEB staining buffer (PBS + 5 mM EDTA + 0.5% BSA, filtered through a 0.1-μm syringe filter membrane).
     2. Add each of the following antibodies into each individual sample: 1) rat anti-mouse PE CD63 antibody (100 ng per reaction); 2) rat anti-mouse PE CD81 (500 ng); 3) rat anti-mouse FITC CD9 (200 ng). Incubate at 4 °C, rocking for 60 min in the dark.
     3. Dilute the samples with 450 μL of membrane-filtered PEB staining buffer and subject the samples to flow cytometry analysis (see **Table of Materials**)25.
     4. Adjust the flow cytometer settings as follows: 1) set all channels on hyper log (hlog); 2) set the trigger on SSC at 4; 3) turn off the secondary trigger. Run the samples in a low-speed setting and acquire at least 10,000 events in each sample.
     5. Perform low cytometry data analysis in each sample using analysis software (see **Table of Materials**).

**REPRESENTATIVE RESULTS:**

We performed EV isolation from mouse BALF using UFC and UC-DGC isolation methods on the same day. The UFC method required approximately 2.5 - 3 h, whereas the UC-DGC technique required 8 h of processing time. This did not include buffers and reagent preparation time. It should be noted that some other tasks could be performed during the long centrifugation periods. Nevertheless, the entire procedure lasted nearly an entire day for the UC-DGC isolation technique.

BALF-derived EVs from normal mice isolated by the UFC method displayed a smaller size and a more uniform size distribution (148.8 ± 1.1 nM, **Figure 1A**) compared to UC-DGC EVs (176.7 ± 7.8 nM, **Figure 1B**). The UFC technique had a profound 65-fold greater total particle counts when compared to UC-DGC isolation (29.4 ± 18.4 *vs.* 0.5 ± 0.1 x 1010 particles;*p*< 0.05; **Table 2** and **Figure 1C**). The total protein recovery (in µg) of the UFC EVs was also higher (3,136 ± 1,860 *vs.* 73.7 ± 38.3 µg;*p*< 0.05; **Table 2** and **Figure 1D**). Thus, UFC is time- and effort-efficient and provides a higher EV yield.

To further phenotypically characterize BALF-derived EV populations, we examined the presence of commonly known exosome surface protein markers: CD63, CD9, and CD81 by flow cytometry and TSG101 by immunoblotting. Using flow cytometry analysis, we demonstrated that UFC EVs and UC-DGC EVs both expressed CD63 (**Figures 2A** - **2C**),CD9 (**Figures 2D** - **2F**), and CD81 (**Figures 2G** - **2I**).The geometric mean expression (gMFI) of CD63, CD9, and CD81 was quantified and not statistically different between the two conditions (**Figures 3A** - **3F**).

Next, we examined another EV protein marker, TSG101, by immunoblotting. We showed that the 20 µg of the UFC flow-through (UFC-FT) sample did not contain TSG101 proteins, suggesting that the UFC isolation technique efficiently selected and retained the EV population from the BALF sample (**Figure 4**). When equal amounts of total protein (20 µg) from the BALF-EV sample was loaded, we found that UFC EVs expressed a higher level of TSG101 than UC-DGC EVs (**Figure 4**). We also showed that the purity of UFC-EV protein was acceptable, demonstrated by a single isolated protein band.

For all results, Student’s *t*-test was used for two-group comparison. The results are presented as mean ± SEM (standard error of the mean), and *p* < 0.05 was considered significant.

**TABLE AND FIGURE LEGENDS:**

**Figure 1: Ultrafiltration centrifugation of murine bronchoalveolar lavage fluid (BALF)-derived EVs demonstrated a more homogenous size distribution than ultracentrifugation with density gradient centrifugation of murine BALF-derived EVs and had a significantly higher total particle count and protein content.** The distribution of EV particle sizes was measured by nanoparticle tracking analysis (NTA), and the total protein content was measured by the bicinchoninic acid assay. (**A**)UFC-BALF EVs’ NTA size distribution graph. (**B**)UC-DGC-BALF EVs’ size distribution graph. (**C**) Total particle count by NTA (mean ± SEM x 1010 particles; \* *p* < 0.05). (**D**) Total protein content (in µg, \* *p* < 0.05). The data were derived from three independent experiments. UFC = ultrafiltration centrifugation; UC-DGC = ultracentrifugation with density gradient centrifugation; EVs = extracellular vesicles; SD = standard deviation; Conc = concentration.

**Figure 2: Murine bronchoalveolar lavage fluid-derived EVs isolated by ultrafiltration centrifugation and ultracentrifugation with density gradient centrifugation methods expressed tetraspanin proteins CD63, CD9, and CD81.** Shown are percentages of EVs stained positive by the UFC and UC-DCG isolation techniques, illustrated by pseudocolor plots, for (**A** - **C**) PE-CD63, (**D** - **F**) FITC-CD9,and (**G** - **I**) PE-CD9. The data are derived from three independent experiments. UFC = ultrafiltration centrifugation; UC-DGC = ultracentrifugation with density gradient centrifugation; EVs = extracellular vesicles; SSC-A = side scatter analysis; PE = phycoerythrin; FITC = fluorescein isothiocyanate.

**Figure 3: Ultrafiltration centrifugation-isolated murine bronchoalveolar lavage fluid-derived EVs expressed a similar fluorescent density of tetraspanin proteins to ultracentrifugation-isolated EVs.** (**A** and **D**) Histogram and geometric mean expression (gMFI) of PE-CD63+-stained EVs. (**B** and **E**) Histogram and gMFI of FITC-CD9+-stained EVs. (**C** and **F**) Histogram and gMFI of PE-CD81+-stained EVs. These data are derived from three independent experiments. UFC = ultrafiltration centrifugation; UC-DGC = ultracentrifugation with density gradient centrifugation; EVs = extracellular vesicles; SSC-A = side scatter analysis; PE = phycoerythrin; FITC = fluorescein isothiocyanate.

**Figure 4: Murine bronchoalveolar lavage fluid-derived EVs isolated by ultrafiltration centrifugation and ultracentrifugation with density gradient centrifugation methods expressed the exosome surface protein, TSG101.** This panel shows the immunoblotting of murine BALF-derived EVs for the TSG101 antibody (47 kDa). UFC = ultrafiltration centrifugation; UC-DGC = ultracentrifugation with density gradient centrifugation; EVs = extracellular vesicles; FT = flow-through; TSG = tumor susceptibility gene.

**Table 1: Buoyant density gradient buffers.** This table gives the composition and buffer ratio of each gradient solution that was used to purify murine bronchoalveolar lavage fluid-derived extracellular vesicle populations isolated by the ultracentrifugation technique.

\* The working solution was 50% iodixanol (25 mL of density gradient medium [see **Table of Materials**] + 5 mL of diluent solution [pH 7.4 of 0.25 M sucrose + 120 mM HEPES + 0.9 M NaCl]).

\*\* Homogenization medium (pH 7.4 of 0.25 M sucrose + 20 mM HEPES + 150 mM NaCl)

**Table 2: The ultrafiltration centrifugation isolation method provided a high murine bronchoalveolar lavage fluid-derived extracellular vesicle yield.** The particle concentration and total particle count were measured by nanoparticle tracking analysis (NTA). The protein concentration and total amount of protein were measured by a bicinchoninic acid protein assay.

\* BALF EVs’ particle concentration (mean ± SEM x 108/μL from three independent experiments).

**†** BALF EVs’ total particle (mean ± SEM x 1010 particles from three independent experiments).

**‡** BALF EVs’ protein concentration (mean ± SEM µg/µL from three independent experiments).

**§** BALF EVs’ total protein (mean ± SEM µg from three independent experiments).

UFC = ultrafiltration centrifugation; UC-DGC = ultracentrifugation with density gradient centrifugation; Conc = concentration; NTA = nanoparticle tracking analysis; SEM = standard error of the mean.

**DISCUSSION:**

In the past few decades, scientists have unraveled the significances of EVs in cellular homeostasis. More importantly, EVs play major roles in many disease processes by modulating neighboring and distant cells through their bioactive cargo molecules1,21,22,26-30. Future development and advancement in this field profoundly rely upon reliable and efficient methods that not only identify and separate correct subsets of EV populations but also preserve their biological functions for downstream applications10,11,14,31. In the current study, we described a nanomembrane ultrafiltration centrifugation (UFC) method to isolate EVs from mouse BALF. In concordance with other reports, we showed that UFC is simple and results in a high recovery yield and purity and, therefore, is suitable for small biological samples10,17,18,32.

UC-DGC is commonly used and is considered to be the gold standard technique for EV isolation because it provides highly purified EV particles10,14. However, this method is technically cumbersome, time-consuming, labor-intensive, and has low scalability. The newly developed microfluidics-based techniques overcome these limitations, but this approach requires further validation before it can be fully implemented as an alternative method33,34. Thus, appropriate methods that accommodate those difficulties without compromising the purity and scalability of samples are sorely needed, particularly for small-volume biological fluid.

We demonstrated that UFC using a nanomembrane filter device was effective for the EV isolation from BALF specimens. The findings presented here highlight the superiority of the UFC procedure in comparison to the gold standard UC-DGC method due to its simplicity and higher scalability. The ultrafiltration-based approach has become widely adopted to isolate EV from a variety of biological specimens: urine35, cell-conditioned media17, and fetal bovine serum36. The other modular size-based EV isolation technique that uses ultrafiltration as a platform is exosome total isolation chip (ExoTIC)31. This method is also suitable for small sample-size specimens. A few factors, such as filter material and the pore size of the nanomembranes, need to be considered when using the UFC technique because they may affect the properties of recovered EVs. For example, different types of filter membranes resulted in different EV-associated RNA recovery yields from urine18. In this study, we showed that regenerated cellulose (RC) with a 10-kDa MWCO provided the highest mRNA expression of NOP10, OST4, SNRPG, and TOMM7 compared to Hydrosart 10 kDa, or polyethersulfone (PES) of 10 kDa18. We further demonstrated that the RC with 10 kDa had a higher retentate EV recovery than the 100 kDa. Others have characterized urine EVs cargo contents that were affected by the type of isolation techniques37. Our study showed that the 100-kDa MWCO RC membrane provided a satisfactory BALF-derived EV yield with the advantage of much less unwanted proteins in the retentate due to the larger MWCO.

This study demonstrated that the sizes and size distribution of UFC EVs were smaller and more homogeneously distributed than those of UC-DGC EVs. Vesicle aggregation, which is common with UC techniques, may explain the dimension heterogeneity of UC-DGC EVs38. We assessed BALF-derived EV purity by detecting the EV membrane proteins TSG101, CD63, CD9, and CD81, which confirms the presence of exosomes in the retentates. We and others have also used TEM to demonstrate the morphology of the UFC EVs35,39-41. Liu *et al.* used a similar ultrafiltration-based approach to isolate EVs and, when compared to EVs isolated by ultracentrifugation, the proteomic and transcriptomic profiles were similar31. Thus, we describe an ultrafiltration centrifugation method using a regenerated cellulose membrane with an MWCO of 100 kDa as an alternative EV isolation method that is suitable for small biological fluid samples such as bronchoalveolar lavage fluid.

The critical steps using this UFC approach to isolate EVs from biological fluid include the initial nanoporous membrane 0.2-µm filtration to ensure that the enriched particles are in the exosomal size range and the avoidance of applying additional force that can damage or deform the exosome morphology and structures10,42. EVs can adhere to the filtration membrane, which results in lower scalability. Therefore, the volume of the sample should not exceed the recommended amount in each type of filter unit. We chose to use regenerated cellulose, which provided a higher mRNA yield from urine-derived EVs18. The type of filter membranes used can alter the recovery yield and type of EVs. Lastly, even though an MWCO of 100 kDa should eliminate the majority of proteins in the biological fluids, some protein contaminants that were larger than 100 kDa or protein aggregates were observed43. In this case, a washing step is critical to minimize EV and protein aggregation. Moreover, functional studies must be properly controlled in order to fully interpret the results, as non-EV-associated proteins will be present in the UFC EVs.

We conclude that UFC is an alternative approach that is feasible for EV isolation for small- or larger-volume samples. The currently available microfilter units can accommodate up to 15 mL of samples.

**ACKNOWLEDGMENTS:**

The work is supported by the NHLBI/NIH grants HL103868 (to P.C.) and HL137076 (to P.C.), the American Heart Association Grant-in-Aid (to P.C.), and the Samuel Oschin Comprehensive Cancer Institute (SOCCI) Lung Cancer Research Award (to P.C.).

**DISCLOSURES:**

The authors have nothing to disclose.

**REFERENCES:**

1. Thery, C., Zitvogel, L., Amigorena, S. Exosomes: composition, biogenesis and function. *Nature Reviews Immunology.* **2**, 569-579 (2002).

2. Kosaka, N. *et al*. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells. *Journal of Biological Chemistry***. 285** (23), 17442-17452 (2010).

3. Raposo, G., Stoorvogel, W. Extracellular vesicles: Exosomes, microvesicles, and friends. *The Journal of Cell Biology.* **200** (4), 373-383 (2013).

4. Fujita, Y., Kosaka, N., Araya, J., Kuwano, K., Ochiya, T. Extracellular vesicles in lung microenvironment and pathogenesis. *Trends in Molecular Medicine.* **21** (9), 533-542 (2015).

5. Kalluri, R. The biology and function of exosomes in cancer. *Journal of Clinical Investigation.* **126** (4), 1208-1215 (2016).

6. Janowska-Wieczorek, A. *et al.* Microvesicles derived from activated platelets induce metastasis and angiogenesis in lung cancer. *International Journal of Cancer.* **113** (5), 752-760 (2005).

7. Valadi, H. *et al*. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nature Cell Biology.* **9** (6), 654-659 (2007).

8. Colombo, M., Raposo, G., Théry, C. Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles. *Annual Review of Cell and Developmental Biology.* **30** (1), 255-289 (2014).

9. Rocco, G. D., Baldari, S., Toietta, G. Exosomes and other extracellular vesicles-mediated microRNA delivery for cancer therapy. *Translational Cancer Research.* **6** (Supplement 8)*,* S1321-1330 (2017).

10. Peterson, M. F., Otoc, N., Sethi, J. K., Gupta, A., Antes, T. J. Integrated systems for exosome investigation. *Methods.* **87** (1), 31-45 (2015).

11. Xu, R., Greening, D. W., Zhu, H. J., Takahashi, N., Simpson, R. J. Extracellular vesicle isolation and characterization: toward clinical application. *Journal of Clinical Investigation.* **126**, 1152-1162 (2016).

12. Gardiner, C. *et al.* Techniques used for the isolation and characterization of extracellular vesicles: results of a worldwide survey. *Journal of Extracellular Vesicles.* **5** (1), 32945 (2016).

13. Inglis, H. C. *et al*. Techniques to improve detection and analysis of extracellular vesicles using flow cytometry. *Cytometry Part A.* **87** (11), 1052-1063 (2015).

14. Li, P., Kaslan, M., Lee, S. H., Yao, J., Gao, Z. Progress in Exosome Isolation Techniques. *Theranostics.* **7** (3), 789-804 (2017).

15. Willis, G. R., Kourembanas, S., Mitsialis, S. A. Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency. *Frontiers in Cardiovascular Medicine.* **4**, 20389 (2017).

16. Lobb, R. J. *et al.* Optimized exosome isolation protocol for cell culture supernatant and human plasma. *Journal of Extracellular Vesicles.* **4** (1), 27031 (2015).

17. Benedikter, B. J. *et al.* Ultrafiltration combined with size exclusion chromatography efficiently isolates extracellular vesicles from cell culture media for compositional and functional studies. *Scientific Reports.* **7** (1), 15297 (2017).

18. Vergauwen, G. *et al.* Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research. *Scientific Reports.* **7** (1), 2704 (2017).

19. Kesimer, M. *et al.* Characterization of exosome-like vesicles released from human tracheobronchial ciliated epithelium: a possible role in innate defense. *The FASEB Journal.* **23** (6), 1858-1868 (2009).

20. Torregrosa Paredes, P. *et al.* Bronchoalveolar lavage fluid exosomes contribute to cytokine and leukotriene production in allergic asthma. *Allergy.* **67** (7), 911-919 (2012).

21. Alipoor, S. D. *et al*. Exosomes and Exosomal miRNA in Respiratory Diseases. *Mediators of Inflammation.* **2016**, 5628404 (2016).

22. Hough, K. P., Chanda, D., Duncan, S. R., Thannickal, V. J., Deshane, J. S. Exosomes in Immunoregulation of Chronic Lung Diseases. *Allergy.* **72** (4), 534-544 (2017).

23. Van Hoecke, L., Job, E. R., Saelens, X., Roose, K. Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration. *Journal of Visualized Experiments.* (123), e55398 (2017).

24. Minciacchi, V. R. *et al.* MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer. *Cancer Research.* **77** (9), 2306-2317 (2017).

25. Koliha, N. *et al*. Melanoma Affects the Composition of Blood Cell-Derived Extracellular Vesicles. *Frontiers in Immunology.* **7**, 581 (2016).

26. Thery, C., Ostrowski, M., Segura, E. Membrane vesicles as conveyors of immune responses. *Nature Reviews Immunology.* **9**, 581-593 (2009).

27. Camussi, G., Deregibus, M. C., Bruno, S., Cantaluppi, V., Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. *Kidney International.* **78** (9), 838-848 (2010).

28. Lee, Y., Andaloussi, El, S., Wood, M. J. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. *Human Molecular Genetics.* **21**, R125-34 (2012).

29. Villarroya-Beltri, C., Baixauli, F., Gutiérrez-Vázquez, C., Sánchez-Madrid, F., Mittelbrunn, M. Sorting it out: Regulation of exosome loading. *Seminars in Cancer Biology.* **28**, 3-13 (2014).

30. Hoshino, A. Tumour exosome integrins determine organotropic metastasis. *Nature.* **527**, 329-335 (2015).

31. Liu, F. *et al.* The Exosome Total Isolation Chip. *ACS Nano.* **11** (11), 10712-10723 (2017).

32. Cheruvanky, A. *et al.* Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. *American Journal of Physiology-Renal Physiology.* **292** (5), F1657-F1661 (2007).

33. Zhao, Z., Yang, Y., Zeng, Y., He, M. A Microfluidic ExoSearch Chip for Multiplexed Exosome Detection Towards Blood-based Ovarian Cancer Diagnosis. *Lab on a Chip.* **16** (3), 489-496 (2016).

34. Fang, S. *et al.* Clinical application of a microfluidic chip for immunocapture and quantification of circulating exosomes to assist breast cancer diagnosis and molecular classification. *PloS ONE.* **12** (4), e0175050 (2017).

35. Cheruvanky, A. *et al.* Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. *American Journal Physiology-Renal Physiology.* **292** (5), F1657-F1661 (2007).

36. Kornilov, R. *et al.* Efficient ultrafiltration-based protocol to deplete extracellular vesicles from fetal bovine serum. *Journal of Extracellular Vesicles.* **7** (1), 1422674 (2018).

37. Alvarez, M. L., Khosroheidari, M., Kanchi Ravi, R., DiStefano, J. K. Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. *Kidney International.* **82** (9), 1024-1032 (2012).

38. Bosch, S. *et al.* Trehalose prevents aggregation of exosomes and cryodamage. *Scientific Reports.* **6** (1), 329 (2016).

39. Xiao, J. *et al.* Cardiac progenitor cell-derived exosomes prevent cardiomyocytes apoptosis through exosomal miR-21 by targeting PDCD4. *Cell Death & Disease.* **7** (6), e2277 (2016).

40. Agarwal, U. *et al.* Experimental, Systems and Computational Approaches to Understanding the MicroRNA-Mediated Reparative Potential of Cardiac Progenitor Cell-Derived Exosomes From Pediatric Patients. *Circulation Research.* **120** (4), 701-712 (2017).

41. Merchant, M. L. *et al.* Microfiltration isolation of human urinary exosomes for characterization by MS. *PROTEOMICS – Clinical Applications.* **4** (1), 84-96 (2010).

42. Gouin, K. *et al.* A comprehensive method for identification of suitable reference genes in extracellular vesicles. *Journal of Extracellular Vesicles.* **6** (1), 1347019 (2017).

43. Betsuyaku, T. *et al.* Neutrophil Granule Proteins in Bronchoalveolar Lavage Fluid from Subjects with Subclinical Emphysema. *American Journal of Respiratory and Critical Care Medicine.* **159** (6), 1985-1991 (1999).